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Due to the beneﬁcial roles played by histamine 3 receptor
(H3R) in alertness, wake-promotion and cognition in central
nervous system (CNS), the research in this ﬁeld has become
a subject of intense interest in recent years (Singh et al.,
2013). Thus the development of potent H3R antagonists has
emerged as an attractive target for the treatment of various
CNS disorders including narcolepsy, ADHD, and cognitive
disorders either as a primary indication or associated with
another disease state (Berlin et al., 2011; Vohora and
Bhowmik, 2012; Celanire et al., 2005). Our interest in H3R
antagonists originated from modaﬁnil (compound 1, Fig. 1)
a novel alertness and wake-promoting agent whose mechanism
of action at the molecular level remains elusive to date (Saper
and Scammell, 2004). Modaﬁnil does not display any signiﬁ-
cant in vitro binding afﬁnity for the H3 receptor. However, it
has been reported that in anesthetized rats, modaﬁnil increased
extracellular histamine concentrations (Ishizuka et al., 2003).Thus while designing a series of H3R antagonists, we sought
to incorporate some of modaﬁnil’s structural themes, espe-
cially its lipophilic bis-aryl moiety attached to a polar (i.e. sul-
ﬁnyl) moiety. In a previous report, we disclosed results from
our initial effort (Dunn et al., 2014). In this Communication,
we offer a brief summary from our additional effort.
2. Chemistry
Scheme 1 depicts the synthesis of target compounds 9–10. Pyr-
idine derivative 2 was coupled with the boronic acid 3 under
Suzuki condition to generate compound 4. Separately, enanti-
omerically pure prolinols (compounds 5–6) underwent reduc-
tive amination reactions with cyclobutanone to generate
amino alcohols 7–8. O-alkylation of compounds 7–8 with com-
pound 4 generated compounds 9 and 10, respectively.
In Scheme 2, the chloro group of compound 2 was dis-
placed by the alkoxides generated from cyclic alkanols 11–13
to produce a series of compounds of general structure 14. Sep-
arately, phenol derivative 15 underwent a Mitsunobu reaction
with compound 13 to produce compound of general structure
16. Compounds 14 and 16 underwent separate Suzuki reac-
tions with 4-(methylsulfonyl)benzeneboronic acid to generate
compounds of general structure 17 that were N-deprotected
to produce free amines of general structure 18. Reductive ami-
nation of compounds 18 with a set of cyclic ketones produced
target compounds 19–25.
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Figure 1 Chemical structure of compound 1.
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Following a literature procedure, binding properties of the tar-
get compounds were assessed against recombinant human H3
(hH3) and rat H3 (rH3) receptors by displacement of [
3H]-N-
a-methylhistamine and reported as Ki values from an average
of three experiments, done in duplicate (US Patent, 2012),X
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 2    X = N, Y = Cl
15   X = C, Y = OH
11 m = 0, R-isomer
12 m = 0, S-isomer
13 m = 1
 19  X = N, m = 1, n = 1
 20  X = N, m = 0, n = 1, S-isomer
 21  X = N, m = 0, n = 2, S-isomer
 22  X = N, m = 0, n = 3, S-isomer
 23  X = N, m = 0, n = 1, R-isomer
 24  X = N, m = 0, n = 2, R-isomer
 25  X = C, m = 1, n = 3
Scheme 2 Reagents and conditions: for compound 14: (a) (i) com
compound 2, 90 C, overnight, 50–60%; for compound 16: (b) PPh3, 4
60%; (c) 4-(methylsulfonyl)benzeneboronic acid, 4-(Pd(PPh3)4, 2 M aq
in dioxane, room temperature, 90–95%; (e) (i) cyclic ketone, gl. AcOH
0 C to room temperature, 4–6 h, 50–60%.
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Scheme 1 Reagents and conditions: (a) 4-(Pd(PPh3)4, 2 M aq. Na2C
AcOH (catalytic), CH2Cl2, 0 C, 20–30 min; (ii) sodium acetoxyboro
DMF, 0 C to room temperature, 30 min; (ii) compound 4, 100 C, 2while in triplicate for the potent analogs. The results are dis-
played in Table 1. The table also displays the result for a ref-
erence compound Pitolisant that entered into clinical trials
(Schwartz, 2011).
4. Discussion
As mentioned previously, compound 1 displayed no hint of
any in vitro binding afﬁnity (even at higher concentrations)
for either H3 receptor. Thus, our exploration began by re-ori-
enting the aromatic region into a para-linked bi-aryl system,
especially an aryl-heteroaryl system as the central lipophilic
region. While a polar sulfonyl group was appended to the aryl
ring, the heteroaryl moiety was attached via a methyleneoxy
moiety, to a terminal cyclic amine moiety to impart some
structural rigidity in that part of the molecule. Initially,
structural fragments derived from (S)- and (R)- prolinol were()m
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14 X = N
16 X = C
(X = N, C)
pounds 11–13, 60%NaH, NMP, 0 C to room temperature; (ii)
0% DEAD in toluene, THF, 0 C to room temperature, overnight,
. Na2CO3, toluene, EtOH, 95–100 C, 6–8 h, 50–60% (d) 4 N HCl
(catalytic), CH2Cl2, 0 C, 30 min; (ii) sodium acetoxyborohydride,
N Cl
O
Me
OS
N
N
O
Me
OS
O
H * 9 = S-isomer
10 = R-isomer
a
4
O3, toluene, EtOH, 95–100 C, 3 h, 70%; (b) (i) cyclobutanone, gl.
hydride, 0 C to room temperature, 4–6 h, 60–65%; (c) (i) NaH,
h, 40–45%.
Table 1 Biological data for the target compounds.
Compound hH3 Ki (nM)
a rH3 Ki (nM)
a
1 b b
9 >1000 >1000
10 >1000 >1000
19c 7 ± 2 18 ± 3
20c 19 ± 3 62 ± 4
21c 19 ± 4 63 ± 4
22c 22 ± 2 20 ± 3
23 234 >1000
24 115 >1000
25 82 276
26 >1000 >1000
Pitolisantd 0.3–1.0 17
a n= 2.
b not active.
c n= 3.
d reference compound (data from Schwartz, J-C, 2011).
Potent histamine-3 receptor antagonists 191utilized to generate compounds 9 and 10, respectively. The lack
of reasonable activity of both compounds 9 and 10 (Table 1)
indicated that this initial maneuver was not productive. It
was postulated that the basic amine moiety in either com-
pound probably was unable to interact with a critical aspartate
residue on the receptor, essential for a productive binding to
H3R. Subsequently, the decision was made to incorporate
the exocyclic methylene group of either compound as a part
of a cyclic moiety, thus generating achiral 2-pyridyl-4-oxypipe-
ridnyl- derivative 19 that imparted immediate potency in both
assays (Ki of 7 nM and 18 nM, respectively). To expand the
scope of the series, the 4-oxypiperidinyl group in compound
19 was subsequently replaced by chiral 3-oxypyrrolidinyl sys-
tems. In the (S)-series of ligands, variation of the size (n= 4
– 5) of the cycloalkyl groups attached to the basic nitrogen
generated compounds 20–22 that displayed similar afﬁnity in
the hH3 binding assay, but they differed ca. 3-fold in rH3 bind-
ing assay (Ki 19–22 nm vs. 62–63 nM). From the (R)-series, the
ligands appeared to possess at least one order of magnitude
lower afﬁnity than their corresponding counterpart from (S)-
series in the hH3 assay (cf. afﬁnities of compound 23 vs. com-
pound 20, and compound 24 vs. compound 21, respectively).
Compounds 23–24 appeared to be signiﬁcantly less active in
the rH3 assay also. The reason for this difference in binding
activity of compounds 23–24 in two assays is not currently
understood. Thus, the chirality of the 3-oxypyrrolidinyl moiety
played a role in the binding activity of this class of ligand. Sub-
sequently, the pyridyl group of compound 22 was replaced by
a phenyl group generating compound 25 that appeared to have
somewhat lower afﬁnity than the parent compound. Finally,
the replacement of the entire methylsulfonylphenyl moiety ofN
Br
O
26
Figure 2 Chemical structure of compound 26.this class of ligands with a smaller lipophilic group (e.g. bro-
mine as in compound 26, Fig. 2) resulted in signiﬁcant loss
of afﬁnity (cf. compound 26 vs. compound 25) indicating
importance of the methylsulfonylphenyl group in the binding
afﬁnity of this class of ligands. Representative compounds 19
and 21 were advanced to pharmacokinetic studies in rats. Both
compounds were detected in the brain in reasonable level post
1 h ip administration (dose 10 mg/kg). Additional proﬁling is
continuing with several members of the series. After comple-
tion of this research, a report of a set of bis-phenyl derivatives
appeared in the literature without mentioning any aryl-hetero-
aryl combination from this current series (Semple et al., 2012).5. Conclusions
In this Communication, utilizing modaﬁnil as a launching pad,
a series of para phenyl-pyridyl aromatic system compounds
that bind potently to both mouse and human recombinant his-
tamine-3 receptors were developed. In PK experiments, repre-
sentative compounds 19 and 21 displayed brain permeability
post 1 h ip administrations.Acknowledgment
Author wishes to acknowledge the scientiﬁc support provided
by the members of the biology team.
Appendix
Rat H3 assay
Cell line development and membrane preparation
The rat H3 receptor cDNA was PCR ampliﬁed from reverse-
transcribed RNA pooled from rat thalamus, hypothalamus,
striatum and prefrontal cortex with a sequence corresponding
to bp #338–1672 of Genbank ﬁle #NM_05306, encoding the
entire 445-amino acid rat histamine H3 receptor. This was
engineered into the pIRES-neo3 mammalian expression vec-
tor, which was stably transfected into the CHO-A3 cell line
(Euroscreen, Belgium), followed by clonal selection by limiting
dilution. Cells were harvested and cell pellets were frozen
(80 C). Cell pellets were re-suspended in 5 mM Tris–HCl,
pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors
(Complete Protease Inhibitor Tablets, Roche Diagnostics).
Cells were disrupted using a polytron cell homogenizer and
the suspension was centrifuged at 1000·g for 10 min at 4 C.
The pellet was discarded and the supernatant was centrifuged
at 40,000·g for 30 min at 4 C. The membrane pellet was
washed in membrane buffer containing 50 mM Tris–HCl, pH
7.5 with 0.6 mM EDTA, 5 mMMgCl2 and protease inhibitors,
re-centrifuged as above and the ﬁnal pellet re-suspended in
membrane buffer plus 250 mM sucrose and frozen at 80 C.
Radioligand binding
Membranes were re-suspended in 50 mM Tris HCl (pH 7.4),
5 mM MgCl2 and 0.1% BSA. The membrane suspensions
(10 lg protein per well) were incubated in a 96 well microtiter
plate with [3H]-N-alpha-methylhistamine (approx. 1 nM ﬁnal
concentration), test compounds at various concentrations
(0.01 nM–30 lM) and scintillation proximity beads (Perkin
192 S. ChatterjeeElmer, FlashBlue GPCR Scintillating Beads) in a ﬁnal volume
of 80 ll for 4 h at room temperature, shielded from light. Non-
speciﬁc binding was determined in the presence of 10 lM clo-
benpropit. Radioligand bound to receptor, and therefore in
proximity to the scintillation beads, was measured using a
Microbeta scintillation counter.
Human H3 assay
Cell line development and membrane preparation
CHO cells stably expressing the human H3 receptor (GenBank:
NM_007232) were harvested and cell pellets were frozen
(80 C). Cell pellets were re-suspended in 5 mM Tris–HCl,
pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors
(Complete Protease Inhibitor Tablets, Roche Diagnostics).
Cells were disrupted using a polytron cell homogenizer and
the suspension was centrifuged at 1000·g for 10 min at 4 C.
The pellet was discarded and the supernatant was centrifuged
at 40,000·g for 30 min at 4 C. This membrane pellet was
washed in membrane buffer containing 50 mM Tris–HCl, pH
7.5 with 0.6 mM EDTA, 5 mMMgCl2 and protease inhibitors,
re-centrifuged as above and the ﬁnal pellet re-suspended in
membrane buffer plus 250 mM sucrose and frozen at 80 C.
Radioligand binding
Membranes were re-suspended in 50 mM Tris HCl (pH 7.4),
5 mM MgCl2 and 0.1% BSA. The membrane suspensions
(10 lg protein per well) were incubated in a 96 well microtiter
plate with [3H]-N-alpha-methylhistamine (approx. 1 nM ﬁnal
concentration), test compounds at various concentrations
(0.01 nM–30 lM) and scintillation proximity beads (Perkin
Elmer, FlashBlueGPCR Scintillating Beads) in a ﬁnal volume
of 80 ll for 4 h at room temperature, shielded from light.Non-speciﬁc binding was determined in the presence of
10 lM clobenpropit. Radioligand bound to receptor, and
therefore in proximity to the scintillation beads, was measured
using a Microbeta scintillation counter.References
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